Judge Rules For Glaxo In Zofran Patent Case

Law360, New York (July 28, 2005, 12:00 AM EDT) -- A federal judge in New Jersey has issued a summary judgment ruling that a subsidiary of Par Pharmaceuticals infringed GlaxoSmithKline's patents for anti-nausea treatment Zofran when it filed an application to make a generic version of the drug.

Judge Jose L. Linares with the U.S. District Court for the District of New Jersey ruled that GlaxoSmithKline's U.S. Patent Nos. 5,578,628 and 4,753,789 for Zofran Orally Disintegrating Tablets are valid, enforceable and infringed by Par's wholly-owned subsidiary, Kali Laboratories, the company said in a statement.

The '628...
To view the full article, register now.